7XQ6 image
Deposition Date 2022-05-06
Release Date 2023-03-01
Last Version Date 2023-11-29
Entry Detail
PDB ID:
7XQ6
Title:
The complex structure of mutant Mpro with inhibitor
Biological Source:
Host Organism:
Method Details:
Experimental Method:
Resolution:
2.00 Å
R-Value Free:
0.23
R-Value Work:
0.18
R-Value Observed:
0.19
Space Group:
C 1 2 1
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:3C-like proteinase nsp5
Mutations:H41N
Chain IDs:A
Chain Length:307
Number of Molecules:1
Biological Source:Severe acute respiratory syndrome coronavirus 2
Ligand Molecules
Primary Citation
Detailed Insights into the Inhibitory Mechanism of New Ebselen Derivatives against Main Protease (M pro ) of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2).
Acs Pharmacol Transl Sci 6 171 180 (2023)
PMID: 36650888 DOI: 10.1021/acsptsci.2c00203

Abstact

SARS-CoV-2 main protease (Mpro/3CLpro) is a crucial target for therapeutics, which is responsible for viral polyprotein cleavage and plays a vital role in virus replication and survival. Recent studies suggest that 2-phenylbenzisoselenazol-3(2H)-one (ebselen) is a potent covalent inhibitor of Mpro, which affects its enzymatic activity and virus survival. Herein, we synthesized various ebselen derivatives to understand the mechanism of Mpro inhibition by ebselen. Using ebselen derivatives, we characterized the detailed interaction mechanism with Mpro. We discovered that modification of the parent ebselen inhibitor with an electron-withdrawing group (NO2) increases the inhibition efficacy by 2-fold. We also solved the structure of an Mpro complex with an ebselen derivative showing the mechanism of inhibition by blocking the catalytic Cys145 of Mpro. Using a combination of crystal structures and LC-MS data, we showed that Mpro hydrolyzes the new ebselen derivative and leaves behind selenium (Se) bound with Cys145 of the catalytic dyad of Mpro. We also described the binding profile of ebselen-based inhibitors using molecular modeling predictions supported by binding and inhibition assays. Furthermore, we have also solved the crystal structure of catalytically inactive mutant H41N-Mpro, which represents the inactive state of the protein where the substrate binding pocket is blocked. The inhibited structure of H41N-Mpro shows gatekeeper residues in the substrate binding pocket responsible for blocking the substrate binding; mutation of these gatekeeper residues leads to hyperactive Mpro.

Legend

Protein

Chemical

Disease

Primary Citation of related structures